Latest Investments News

St Barbara updates shareholders on its ongoing strategic review, highlighting stalled Atlantic separation talks and advancing Simberi sale discussions, while reaffirming commitment to a major expansion.

St Barbara Limited forecasts a 21% increase in gold production for FY26 at its Simberi Operations, with costs expected between A$4,000 and A$4,400 per ounce. However, key capital investment decisions hinge on unresolved Papua New Guinea tax assessments and mining lease approvals.

TerraCom Limited reports a $43.4 million net loss for FY25, reflecting increased impairment charges and operational challenges, while advancing its strategic Moorlands Project in Australia.

Betashares Capital Ltd has announced the final distribution amounts payable for September 2025 across a broad suite of its ETFs, providing key dates and reinvestment plan details for investors.

Wellnex Life Limited reported a robust 40.5% revenue increase in FY25, driven by the full-year integration of Pain Away, while margin recovery gains momentum in the second half.

Renergen Limited reports significant progress on its merger with ASP Isotopes, resolves a key dispute with Springbok Solar, and reveals promising exploration developments, while managing production and financial challenges.

Quantum Graphite Ltd reported a significant revenue jump alongside a $4.9 million net loss for FY2025, as it pushes forward with its Uley 2 graphite project backed by major infrastructure and funding initiatives.

EMVision Medical Devices has launched a Share Purchase Plan allowing shareholders to invest up to A$30,000 at $1.94 per share, sweetened by free-attaching options exercisable at $3.40 each.

Ryzon Materials has expanded its engineering contract with Xinhai to fast track production at its Nachu Graphite Project, alongside a $500,000 capital raising from Xinhai. The deal involves a $3.5 million contract largely settled through shares and options, pending shareholder approval.

Uscom Limited has struck a deal to sell its entire business to Singapore-based AXO Medtech VCC for $2.59 million, aiming to unlock capital for growth under new ownership. Shareholder approval is the next critical step before the transaction can proceed.

Invex Therapeutics has discontinued exclusive negotiations to acquire a rare neurological disease company due to board instability triggered by a shareholder requisition notice. Despite this setback, the company remains committed to diversifying its neurological treatment portfolio.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.